Travere Therapeutics, Inc. (TVTX)
$
31.09
-0.90 (-2.89%)
Key metrics
Financial statements
Free cash flow per share
-0.9003
Market cap
2.9 Billion
Price to sales ratio
6.5673
Debt to equity
4.4825
Current ratio
2.7475
Income quality
0.6620
Average inventory
4.8 Million
ROE
-1.7868
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The weighted average number of shares outstanding is 78,889,000.00 highlighting the company's shareholder base. The net total of other income and expenses is $3,317,000.00 reflecting non-core financial activities. The income before tax ratio is -1.37 reflecting the pre-tax margin. Meanwhile, the EBITDA ratio is -1.14 highlighting the company's operational efficiency. Additionally, the weighted average number of diluted shares outstanding is 78,889,000.00 reflecting potential dilution effects as it navigates its market position. Travere Therapeutics, Inc. operates within the biopharmaceutical landscape, focusing on the identification, development, and commercialization of therapies for rare diseases. Its marketed products include Chenodal, a synthetic oral formulation for treating radiolucent stones in gallbladders, Cholbam, a cholic acid capsule for various bile acid synthesis disorders, and Thiola and Thiola EC for treating homozygous cystinuria. Additionally, the company's product candidates include Sparsentan and TVT-058, targeting serious nephrological conditions through clinical trials. Through its cooperative research and development agreements, Travere seeks to advance treatment options for conditions such as NGLY1 deficiency and Alagille syndrome. The stock is affordable at $24.85 suitable for budget-conscious investors. The stock has a high average trading volume of 2,215,848.00 indicating strong liquidity in the marketplace. With a market capitalization of $2,781,693,807.00 the company is classified as a small-cap player within the industry. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the healthcare sector, driving innovation and growth while maintaining a commitment to improving the lives of patients with rare diseases. Through its structured approach and dedicated research, Travere Therapeutics continues to make strides in advancing therapeutic solutions, positioning itself as a vital entity in the quest for novel treatments for challenging health conditions.
Is Travere Therapeutics, Inc. (TVTX) a good investment?
Investing in Travere Therapeutics, Inc. (TVTX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Travere Therapeutics, Inc. (TVTX)'s stock forecast?
Analysts predict Travere Therapeutics, Inc. stock to fluctuate between $12.91 (low) and $42.13 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Travere Therapeutics, Inc.'s market capitalization?
As of 2026-01-30, Travere Therapeutics, Inc.'s market cap is $2,781,693,807, based on 89,472,300 outstanding shares.
How does Travere Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Travere Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Travere Therapeutics, Inc. (TVTX) stock?
To buy Travere Therapeutics, Inc. (TVTX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TVTX. Place an order (Market, Limit, etc.).
What is the best time to invest in Travere Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Travere Therapeutics, Inc. stock ever split?
Travere Therapeutics, Inc.'s last stock split was 1:9 on 2012-11-02.
How did Travere Therapeutics, Inc. perform in the last earnings report?
Revenue: $233,175,000 | EPS: -$4.08 | Growth: 172%.
Where can I find Travere Therapeutics, Inc.'s investor relations reports?
Visit https://www.travere.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Travere Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Travere Therapeutics, Inc. stock?
All-time high: $42.13 (2025-12-24) | All-time low: $5.12 (2024-04-25).
What are the key trends affecting Travere Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
SAN DIEGO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-travere-therapeutics-inc-investigation-tvtx.html You can also contact attorney J.C.
prnewswire.com
SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-travere-therapeutics-inc-investigation-tvtx.html You can also contact attorney J.C.
globenewswire.com
BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Travere Therapeutics, Inc. (Nasdaq: TVTX) for potential securities law violations. Investors who have lost money in their Travere Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.
fool.com
Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (AUM).
fool.com
Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (AUM).
businesswire.com
SAN DIEGO--(BUSINESS WIRE)---- $TVTX #TVTX--Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements to investors.
zacks.com
Travere Therapeutics shares fall after the FDA extends its review timeline for Filspari's sNDA in FSGS, pushing the decision date to April 2026.
fool.com
The FDA has extended its review of the company's Filspari. This is a setback for the biotech's leading drug candidate.
globenewswire.com
SAN DIEGO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-travere-therapeutics-inc-investigation-tvtx.html You can also contact attorney J.C.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026. The extension follows the recent submission of responses requested by the FDA to further characterize the clinical benefit o.
See all news
